Assignee
BERG LLC
US·29 granted patents·52 pending applications·78 citations·filing 2013–2024
Top patents by PatentIndex Score
81 records- 0197US11028446B2Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)BERG LLC·Filed 2019·Granted Jun 8, 2021·6 cites·15 claims
- 0295US10351915B2Methods for treatment of oncological disorders using an epimetabolic shifter (Coenzyme Q10)BERG LLC·Filed 2018·Granted Jul 16, 2019·10 cites·9 claims
- 0395US9896731B2Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)BERG LLC·Filed 2014·Granted Feb 20, 2018·15 cites·18 claims
- 0489US10376477B2Method of treating or preventing tumors of the central nervous systemBERG LLC·Filed 2016·Granted Aug 13, 2019·6 cites·24 claims
- 0589US9901542B2Methods of treatment of cancer by continuous infusion of coenzyme Q10BERG LLC·Filed 2014·Granted Feb 27, 2018·10 cites·53 claims
- 0688US11305016B2Vitamin D3 and analogs thereof for treating alopeciaBERG LLC·Filed 2018·Granted Apr 19, 2022·1 cites·20 claims
- 0786US10588859B2Topical formulations having enhanced bioavailabilityBERG LLC·Filed 2013·Granted Mar 17, 2020·6 cites·28 claims
- 0886US2024161863A1Interrogatory cell-based assays for identifying drug-induced toxicity markersBERG LLC·Filed 2024·Application pending·0 cites
- 0985US11456054B2Interrogatory cell-based assays and uses thereofBERG LLC·Filed 2018·Granted Sep 27, 2022·2 cites·27 claims
- 1084US11298313B2Methods of treatment of cancer by continuous infusion of coenzyme Q10BERG LLC·Filed 2018·Granted Apr 12, 2022·1 cites·36 claims
- 1184US11091447B2UBE2K modulators and methods for their useBERG LLC·Filed 2020·Granted Aug 17, 2021·1 cites·8 claims
- 1283US10933032B2Methods for the treatment of cancer using coenzyme Q10 combination therapiesBERG LLC·Filed 2014·Granted Mar 2, 2021·3 cites·32 claims
- 1383US2025123283A1Use of markers including filamin a in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2024·Application pending·0 cites
- 1482US10539566B2Use of markers including filamin A in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2015·Granted Jan 21, 2020·3 cites·23 claims
- 1581US10482385B2Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient dataBERG LLC·Filed 2015·Granted Nov 19, 2019·4 cites·54 claims
- 1678US10668028B2Methods and use of inducing apoptosis in cancer cellsBERG LLC·Filed 2015·Granted Jun 2, 2020·1 cites·4 claims
- 1778US10352947B2Use of markers in the identification of cardiotoxic agents and in the diagnosis and monitoring of cardiomyopathy and cardiovascular diseaseBERG LLC·Filed 2013·Granted Jul 16, 2019·3 cites·14 claims
- 1877US2023147697A1Topical formulations having enhanced bioavailabilityBERG LLC·Filed 2022·Application pending·0 cites
- 1977US2022023317A1Preventing or mitigating chemotherapy induced alopecia using vitamin dBERG LLC·Filed 2021·Application pending·0 cites
- 2076US2021002725A1Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencesBERG LLC·Filed 2020·Application pending·0 cites
- 2176US2021332439A1Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencersBERG LLC·Filed 2020·Application pending·0 cites
- 2274US11452699B2Method of treating or preventing tumors of the central nervous systemBERG LLC·Filed 2019·Granted Sep 27, 2022·0 cites·27 claims
- 2373US10759850B2Filamin A binding proteins and uses thereofBERG LLC·Filed 2017·Granted Sep 1, 2020·1 cites·30 claims
- 2473US9360454B2Methods and kits for detection of coenzyme Q10BERG LLC·Filed 2013·Granted Jun 7, 2016·2 cites·82 claims
- 2573US2023274799A1Systems and methods for patient stratification and identification of potential biomarkersBERG LLC·Filed 2022·Application pending·0 cites
- 2671US2023302022A1Preventing or mitigating chemotherapy induced alopecia using vitamin dBERG LLC·Filed 2022·Application pending·0 cites
- 2771US2026028355A1Proteolysis targeting chimera (protac) compositions using ubiquitin conjugating enzyme ligandsBERG LLC·Filed 2023·Application pending·0 cites
- 2870US11224641B2Enolase 1 (ENO1) compositions and uses thereofBERG LLC·Filed 2018·Granted Jan 18, 2022·0 cites·16 claims
- 2970US2023165809A1INTRAVENOUS FORMULATIONS OF COENZYME Q10 (CoQ10) AND METHODS OF USE THEREOFBERG LLC·Filed 2022·Application pending·0 cites
- 3070US2021077424A1Methods and use of inducing apoptosis in cancer cellsBERG LLC·Filed 2020·Application pending·0 cites
- 3170US2020333344A1Use of markers including filamin a in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2019·Application pending·0 cites
- 3269US10188708B2Enolase 1 (Eno1) compositions and uses thereofBERG LLC·Filed 2015·Granted Jan 29, 2019·1 cites·18 claims
- 3369US2019010554A1Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencesBERG LLC·Filed 2017·Application pending·0 cites
- 3469US2020113918A1Preventing or mitigating chemotherapy induced alopecia using vitamin dBERG LLC·Filed 2019·Application pending·0 cites
- 3568US11694765B2Interrogatory cell-based assays for identifying drug-induced toxicity markersBERG LLC·Filed 2018·Granted Jul 4, 2023·0 cites·17 claims
- 3668US10188707B2Enolase 1 (Eno1) compositions and uses thereofBERG LLC·Filed 2015·Granted Jan 29, 2019·1 cites·26 claims
- 3768US2023142060A1Coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosaBERG LLC·Filed 2022·Application pending·0 cites
- 3867US2021015748A1Topical formulations having enhanced bioavailabilityBERG LLC·Filed 2020·Application pending·0 cites
- 3966US11419830B2Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosaBERG LLC·Filed 2018·Granted Aug 23, 2022·0 cites·17 claims
- 4066US2022107322A1Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancerBERG LLC·Filed 2021·Application pending·0 cites
- 4166US2022137070A1Methods and systems for identifying modulators of pervasive developmental disordersBERG LLC·Filed 2021·Application pending·0 cites
- 4265US2022096399A1Methods of treatment of solid tumors using coenzyme q10BERG LLC·Filed 2021·Application pending·0 cites
- 4364US10114013B2Method for detection of coenzyme Q10BERG LLC·Filed 2016·Granted Oct 30, 2018·1 cites·13 claims
- 4463US9797905B2Use of markers in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2016·Granted Oct 24, 2017·0 cites·33 claims
- 4563US2022002255A1Ube2k modulators and methods for their useBERG LLC·Filed 2021·Application pending·0 cites
- 4663US2018031563A1Use of markers in the diagnosis and treatment of prostate cancerBERG LLC·Filed 2017·Application pending·0 cites
- 4763US2021346291A1Inhalable pharmaceutical compositionsBERG LLC·Filed 2020·Application pending·0 cites
- 4863US2017137879A1Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencersBERG LLC·Filed 2016·Application pending·0 cites
- 4963US2021369645A1Methods for the treatment of cancer using coenzyme q10 combination therapiesBERG LLC·Filed 2021·Application pending·0 cites
- 5063US2016145693A1Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencersBERG LLC·Filed 2015·Application pending·0 cites
Showing the top 50 of 81 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →